Operator Dependent Choice of Prostate Cancer Biopsy Has Limited Impact on a Gene Signature Analysis for the Highly Expressed Genes IGFBP3 and F3 in Prostate Cancer Epithelial Cells

Peng, Zhuochun; Andersson, Karl; Lindholm, Johan; Bodin, Inger; Pramana, Setia; Pawitan, Yudi; Nistér, Monica; Nilsson, Sten; Li, Chunde

doi:10.1371/journal.pone.0109610

Cited by 12 publications

(21 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…86 Conversely, Long et al 86 have demonstrated consistent gene expression across multiple biopsy cores in a single patient, supporting previous work revealing limited variation in gene expression levels of highly expressed genes across multiple biopsy cores, including both malignant and benign stromal tissue. 88 As others have noted, such consistent gene expression, despite tissue and tumor heterogeneity, supports the notion that one can be confident in the overall prostate biology based on analysis of a limited sample. 89 …”

Section: Molecular Testing In Active Surveillancesupporting

confidence: 68%

Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools

Tosoian¹,

Loeb²,

Epstein³

et al. 2016

American Society of Clinical Oncology Educational Book

View full text Add to dashboard Cite

Active surveillance (AS) has emerged as a standard management option for men with very low-risk and low-risk prostate cancer, and contemporary data indicate that use of AS is increasing in the United States and abroad. In the favorable-risk population, reports from multiple prospective cohorts indicate a less than 1% likelihood of metastatic disease and prostate cancer-specific mortality over intermediate-term follow-up (median 5 to 6 years). Higher-risk men participating in AS appear to be at increased risk of adverse outcomes, but these populations have not been adequately studied to this point. Although monitoring on AS largely relies on serial prostate biopsy, a procedure associated with significant morbidity, there is a need for improved diagnostic tools for patient selection and monitoring. Revisions from the 2014 International Society of Urologic Pathology consensus conference have yielded a more intuitive reporting system and detailed reporting of low-intermediate grade tumors, which should facilitate the practice of AS. Meanwhile, emerging modalities such as multiparametric magnetic resonance imaging and tissue-based molecular testing have shown prognostic value in some populations. At this time, however, these instruments have not been sufficiently studied to consider their routine, standardized use in the AS setting. Future studies should seek to identify those platforms most informative in the AS population and propose a strategy by which promising diagnostic tools can be safely and efficiently incorporated into clinical practice.

show abstract

Section: Molecular Testing In Active Surveillancesupporting

confidence: 68%

Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools

Tosoian¹,

Loeb²,

Epstein³

et al. 2016

American Society of Clinical Oncology Educational Book

View full text Add to dashboard Cite

show abstract

“…3 In addition, Long et al demonstrated that there is a strong correlation of gene expression across separate biopsy cores from the same patient, 40 a finding that was similar to that of a study by Peng et al that suggested that there was limited, operator choice-dependent variation in gene signature analysis of highly expressed genes across multiple biopsy samples, primary versus secondary Gleason patterns, and primary versus benign tissue. 41 This consistency of gene expression, regardless of interbiopsy or intrabiopsy tumor heterogeneity, reinforces the current understanding that it is possible to be confident in the biology of the entire prostate based on analysis of gene expression in a biopsy sample.…”

Section: Molecular Risk Profiling As a Substitute For Early Confirmatsupporting

confidence: 59%

Applying precision medicine to the active surveillance of prostate cancer

Reichard

Stephenson

Klein

2015

Cancer

View full text Add to dashboard Cite

The recent introduction of a variety of molecular tests will potentially reshape the care of patients with prostate cancer. These tests may make more accurate management decisions possible for those patients who have been “overdiagnosed” with biologically indolent disease, which represents an exceptionally small mortality risk. There is a wide range of possible applications of these tests to different clinical scenarios in patient populations managed with active surveillance. Cancer 2015;121:3435–43. © 2015 American Cancer Society.

show abstract

“…The sample preparation process is described by Peng et al [ 9 ]. The results reported here were mainly obtained at the same time as the results reported by Peng et al [ 9 ].…”

Section: Methodsmentioning

confidence: 99%

“…Even though the extracted RNA from FFPE samples may be of relatively low quality, multiple recent studies have shown promising results when utilizing degraded RNA extracted from archival FFPE samples for quantifying gene expression levels by optimized RT-qPCR methods [ 6 – 8 ]. One example is the Prostatype RT-qPCR kit, which is developed and optimized for measuring the gene expression levels of a gene signature of IGFBP3, F3 and VGLL3 particularly in FFPE samples [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

“…One important factor when analyzing patient material is to minimize operator dependencies. A recent study reported that the operator dependent choice of FFPE core needle biopsy (with different Gleason patterns) for measurement of expression levels of IGFBP3 and F3 has limited impact on the results, when using the Prostatype RT-qPCR kit [ 9 ]. The effect on VGLL3 measurements could not be estimated in that study due to limited tissue input.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Improving the Prediction of Prostate Cancer Overall Survival by Supplementing Readily Available Clinical Data with Gene Expression Levels of IGFBP3 and F3 in Formalin-Fixed Paraffin Embedded Core Needle Biopsy Material

et al. 2016

Self Cite

View full text Add to dashboard Cite

BackgroundA previously reported expression signature of three genes (IGFBP3, F3 and VGLL3) was shown to have potential prognostic value in estimating overall and cancer-specific survivals at diagnosis of prostate cancer in a pilot cohort study using freshly frozen Fine Needle Aspiration (FNA) samples.MethodsWe carried out a new cohort study with 241 prostate cancer patients diagnosed from 2004–2007 with a follow-up exceeding 6 years in order to verify the prognostic value of gene expression signature in formalin fixed paraffin embedded (FFPE) prostate core needle biopsy tissue samples. The cohort consisted of four patient groups with different survival times and death causes. A four multiplex one-step RT-qPCR test kit, designed and optimized for measuring the expression signature in FFPE core needle biopsy samples, was used. In archive FFPE biopsy samples the expression differences of two genes (IGFBP3 and F3) were measured. The survival time predictions using the current clinical parameters only, such as age at diagnosis, Gleason score, PSA value and tumor stage, and clinical parameters supplemented with the expression levels of IGFBP3 and F3, were compared.ResultsWhen combined with currently used clinical parameters, the gene expression levels of IGFBP3 and F3 are improving the prediction of survival time as compared to using clinical parameters alone.ConclusionThe assessment of IGFBP3 and F3 gene expression levels in FFPE prostate cancer tissue would provide an improved survival prediction for prostate cancer patients at the time of diagnosis.

show abstract

Operator Dependent Choice of Prostate Cancer Biopsy Has Limited Impact on a Gene Signature Analysis for the Highly Expressed Genes IGFBP3 and F3 in Prostate Cancer Epithelial Cells

Cited by 12 publications

References 9 publications

Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools

Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools

Applying precision medicine to the active surveillance of prostate cancer

Improving the Prediction of Prostate Cancer Overall Survival by Supplementing Readily Available Clinical Data with Gene Expression Levels of IGFBP3 and F3 in Formalin-Fixed Paraffin Embedded Core Needle Biopsy Material

Contact Info

Product

Resources

About